SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Eagle Asset Management Inc.

Eagle Asset Management Inc. lowered its holdings in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 16.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 273,479 shares of the company’s stock after selling 54,366 shares during the quarter. Eagle Asset Management Inc. owned approximately 0.37% of SpringWorks Therapeutics worth $9,296,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD lifted its position in shares of SpringWorks Therapeutics by 48.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,110,462 shares of the company’s stock valued at $202,318,000 after buying an additional 1,333,892 shares in the last quarter. Vanguard Group Inc. lifted its holdings in SpringWorks Therapeutics by 8.2% during the first quarter. Vanguard Group Inc. now owns 6,529,325 shares of the company’s stock valued at $321,373,000 after purchasing an additional 492,783 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its holdings in SpringWorks Therapeutics by 16.9% during the second quarter. D. E. Shaw & Co. Inc. now owns 758,712 shares of the company’s stock valued at $28,581,000 after purchasing an additional 109,865 shares in the last quarter. Seven Eight Capital LP acquired a new position in shares of SpringWorks Therapeutics during the 2nd quarter worth about $1,854,000. Finally, Los Angeles Capital Management LLC lifted its stake in SpringWorks Therapeutics by 238.3% in the 3rd quarter. Los Angeles Capital Management LLC now owns 47,212 shares of the company’s stock valued at $1,513,000 after buying an additional 33,255 shares in the last quarter.

SpringWorks Therapeutics Trading Up 7.5 %

Shares of SWTX stock opened at $39.02 on Friday. SpringWorks Therapeutics, Inc. has a twelve month low of $20.19 and a twelve month high of $53.92. The company’s 50-day moving average price is $32.60 and its 200-day moving average price is $36.78. The stock has a market cap of $2.90 billion, a price-to-earnings ratio of -10.06 and a beta of 0.79.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.03. The company had revenue of $49.10 million for the quarter, compared to analyst estimates of $53.28 million. SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%. SpringWorks Therapeutics’s revenue was up 4810.0% on a year-over-year basis. During the same period in the previous year, the business posted ($1.27) EPS. As a group, equities research analysts predict that SpringWorks Therapeutics, Inc. will post -3.14 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on SWTX shares. HC Wainwright reduced their target price on SpringWorks Therapeutics from $76.00 to $74.00 and set a “buy” rating for the company in a report on Tuesday, November 12th. Wedbush restated an “outperform” rating and issued a $77.00 price objective on shares of SpringWorks Therapeutics in a report on Monday, November 18th. JPMorgan Chase & Co. lifted their target price on shares of SpringWorks Therapeutics from $64.00 to $68.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Finally, Evercore ISI began coverage on shares of SpringWorks Therapeutics in a research report on Wednesday. They issued an “outperform” rating and a $60.00 target price for the company. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $67.00.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.